Partners Astrazeneca and Merck have gained a green light from the FDA for U.S. marketing of the oral MEK1/2 inhibitor Koselugo (selumetinib), the first FDA-approved treatment for the rare genetic disorder neurofibromatosis type 1 $AZN $MRK https://t.co/F1t3P13kQw